Synthesis, metabolite analysis, and in vivo evaluation of [11C]irinotecan as a novel positron emission tomography (PET) probe

Nuclear Medicine and Biology

Volumn 40, Issue 5, 2013, Pages 651-657

  Kawamura, Kazunori ^a   Hashimoto, Hiroki ^a   Ogawa, Masanao ^a,b   Yui, Joji ^a   Wakizaka, Hidekatsu ^a   Yamasaki, Tomoteru ^a   Hatori, Akiko ^a   Xie, Lin ^a   Kumata, Katushi ^a   Fujinaga, Masayuki ^a   Zhang, Ming Rong ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b 141 0032   (Japan)

Author keywords

Carbon 11; Column switching HPLC; Irinotecan; Metabolite analysis; Positron emission tomography (PET); Solid phase extraction

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBON 11; CARBON DIOXIDE; DRUG METABOLITE; IRINOTECAN C 11; MULTIDRUG RESISTANCE PROTEIN; PHOSGENE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; CARBON DIOXIDE FIXATION; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; INHIBITION KINETICS; KNOCKOUT MOUSE; LIVER; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION; RADIOACTIVITY; RADIOCHEMISTRY; RADIOISOTOPE DECAY; SMALL INTESTINE; SOLID PHASE EXTRACTION; WHOLE BODY PET; WILD TYPE;

ANIMALS; CAMPTOTHECIN; CARBON RADIOISOTOPES; CHEMISTRY TECHNIQUES, SYNTHETIC; KINETICS; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84878173095     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.03.004     Document Type: Article

References (39)

1. Kunimoto T., Nitta K., Tanaka T., Uehara N., Baba H., Takeuchi M., et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987, 47:5944-5947.
2. Sawada S., Okajima S., Aiyama R., Nokata K., Furuta T., Yokokura T., et al. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamate-linked, water soluble prodrugs of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull 1991, 39:1446-1454.
3. Rothenberg M.L. Irinotecan (CPT-11): recent developments and future directions-colorectal cancer and beyond. Oncologist 2001, 6:66-80.
4. de Jong F.A., de Jonge M.J.A., Verweij J., Mathijssen R.H.J. Role of pharmacogenetics in irinotecan therapy. Cancer Lett 2006, 234:90-106.
5. Saunders M., Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer 2006, 95:131-138.
6. Mathijssen R.H., de Jong F.A., van Schaik R.H., Lepper E.R., Friberg L.E., Rietveld T., et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004, 96:1585-1592.
7. Abigerges D., Chabot G.G., Armand J.P., Hérait P., Gouyette A., Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3weeks in cancer patients. J Clin Oncol 1995, 13:210-221.
8. 14C]CPT-11 in cancer patients. Drug Metab Dispos 2000, 28:423-433.
9. Araki E., Ishikawa M., Iigo M., Koide T., Itabashi M., Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993, 84:697-702.
10. Kudoh S., Fukuoka M., Masuda N., Yoshikawa A., Kusunoki Y., Matsui K., et al. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 1995, 86:406-413.
11. Negoro S., Fukuoka M., Masuda N., Takada M., Kusunoki Y., Matsui K., et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991, 83:1164-1168.
12. Takasuna K., Kasai Y., Kitano Y., Mori K., Kakihata K., Hirohashi M., et al. Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Nihon Yakurigaku Zasshi 1995, 105:447-460.
13. Zhang X.X., Pan W.S., Gan L., Zhu C.L., Gan Y. Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs. Acta Pharmacol Sin 2008, 29:1391-1398.
14. Lokiec F., Canal P., Gay C., Chatelut E., Armand J.P., Roché H., et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 1995, 36:79-82.
15. Mathijssen R.H., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001, 7:2182-2194.
16. Smith N.F., Figg W.D., Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 2006, 20:163-175.
17. Gupta E., Lestingi T.M., Mick R., Ramirez J., Vokes E.E., Ratain M.J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994, 54:3723-3725.
18. Gupta E., Safa A.R., Wang X., Ratain M.J. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A. Cancer Res 1996, 56:1309-1314.
19. Arimori K., Kuroki N., Hidaka M., Iwakiri T., Yamsaki K., Okumura M., et al. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res 2003, 20:910-917.
20. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993, 53:4595-4602.
21. de Bruin M., Miyake K., Litman T., Robey R., Bates S.E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 1999, 146:117-126.
22. Allen J.D., Brinkhuis R.F., Wijnholds J., Schinkel A.H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999, 59:4237-4241.
23. Kruijtzer C.M., Beijnen J.H., Rosing H., ten Bokkel Huinink W.W., Schot M., Jewell R.C., et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002, 20:2943-2950.
24. Malingré M.M., Beijnen J.H., Rosing H., Koopman F.J., Jewell R.C., Paul E.M., et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001, 84:42-47.
25. Jonker J.W., Freeman J., Bolscher E., Musters S., Alvi A.J., Titley I., et al. Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 2005, 23:1059-1065.
26. 4 gas detection tube. Nucl Med Biol 2010, 37:73-76.
27. 2 into carbamates. Angew Chem Int Ed 2009, 48:3482-3485.
28. Wilson A.A., Garcia A., Houle S., Sadovski O., Vasdev N. Synthesis and application of isocyanates radiolabeled with carbon-11. Chemistry Eur J 2011, 17:259-264.
29. 11C-carbonyl]-methylcarbamates. Org Biomol Chem 2010, 8:428-432.
30. 11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. Nucl Med Biol 2011, 38:247-253.
31. 2 fixation for imaging monoamine oxidase B. J Label Compd Radiopharm 2011, 54:678-680.
32. 11C]Ro15-1788 for PET studies of benzodiazepine receptors. Int J Appl Radiat Isot 1985, 36:971-976.
33. 11C]PK11195] and its metabolites in humans. Nucl Med Biol 2005, 32:307-312.
34. Chitneni S.K., Serdons K., Evens N., Fonge H., Celen S., Deroose C.M., et al. Efficient purification and metabolite analysis of radiotracers using high-performance liquid chromatography and on-line solid-phase extraction. J Chromatogr A 2008, 1189:323-331.
35. 11C]-labeled radiopharmaceuticals and their metabolites in plasma. Nucl Med Biol 2009, 36:961-965.
36. Hilton J., Yokoi F., Dannals R.F., Ravert H.T., Szabo Z., Wong D.F. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 2000, 27:627-630.
37. Takei M., Kida T., Suzuki K. Sensitive measurement of positron emitters eluted from HPLC. Appl Radiat Isot 2001, 55:229-234.
38. Werkhoven-Goewie C.E., de Ruiter C., Brinkman U.A., Frei R.W., de Jong G.J., Little C.J., et al. Automated determination of drugs in blood samples after enzymatic hydrolysis using precolumn switching and post-column reaction detection. J Chromatogr 1983, 255:79-90.
39. Yu Z., Westerlund D., Boos K.S. Evaluation of liquid chromatographic behavior of restricted-access media precolumns in the course of direct injection of large volumes of plasma samples in column-switching systems. J Chromatogr B Biomed Sci 1997, 704:53-62.